MedTrace Logo

Home Away From Home - Quality of Life Surveys

NCT02777021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 154

Last updated 2019-12-23

Study results available
· View outcomes & findings →

Summary

Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications. Infectious complications are the leading cause of treatment related mortality among AML patients, but there are little clinical data to inform whether management of neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting. Further, no studies have been conducted that assess the impact of neutropenia management strategy on the quality of life of pediatric patients with AML and their caregivers.

Conditions

  • Pediatric Acute Myeloid Leukemia

Sponsors & Collaborators

  • Children's Healthcare of Atlanta

    collaborator OTHER

  • C.S. Mott Children's Hospital

    collaborator OTHER

  • Ann & Robert H Lurie Children's Hospital of Chicago

    collaborator OTHER

  • Arkansas Children's Hospital Research Institute

    collaborator OTHER

  • Children's Medical Center Dallas

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • Primary Children's Hospital

    collaborator OTHER

  • Children's Hospital of Michigan

    collaborator OTHER

  • Lucile Packard Children's Hospital

    collaborator OTHER

  • St. Jude Children's Research Hospital

    collaborator OTHER

  • Seattle Children's Hospital

    collaborator OTHER

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Alfred I. duPont Hospital for Children

    collaborator OTHER

  • Children's Hospital Colorado

    collaborator OTHER

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • Children's Hospital of Philadelphia

    lead OTHER

Principal Investigators

  • Richard Aplenc, MD, PhD · Children's Hospital of Philadelphia

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-07-18
Completion
2019-07-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02777021 on ClinicalTrials.gov